Effect of Lovastatin on lipoprotein lipid peroxidation and antioxidant status in inflammation induced hyperlipidemic rats

Journal of Chemical and Pharmaceutical Research

Volumn 3, Issue 3, 2011, Pages 52-63

  Chhetri, Samir ^a   Khan, Amir ^b   Rathore, N S ^e   Ishaq, Fouzia ^c   Chandel, Abhay S ^a   Malhotra, Deepti ^d  

^a H N B GARHWAL UNIVERSITY   (India)

^b DIBNS   (India)

^c GURUKUL KANGRI UNIVERSITY   (India)

^d Shri Guru Ram Rai (PG) College   (India)

^e GRAPHIC ERA UNIVERSITY   (India)

Author keywords

Atherosclerosis Lovastatin and Hepatic antioxidant enzymes; CVD; Hypercholesterolemia; Hypolipidemic; Inflammation

Indexed keywords

CATALASE; CHOLESTEROL; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MEVINOLIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; HYPERLIPIDEMIA; INFLAMMATION; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; NONHUMAN; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79957903192     PISSN: None     EISSN: 09757384     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. CD Mathers; A Lopez; C Stein; D MaFat; C Rao; M Inoue. In Disease Control Priorities Project Working 2001 Paper 18. Bethesda, MD.
2. CJ Murray; AD Lopez. Global Comparative Assessments in the Health Sector Disease Burden, Expenditures, and Intervention Packages Geneva., 1994, WHO.
3. The World Health Report. Reducing Risks, Promoting Healthy Life. Geneva., 2002, WHO.
4. EA Enas; S Yusuf; JL Mehta. Am. J. Cardiol., 1992. 70(9): 945-9
5. KR Feingold; I Staprans; RA Memon. J. Lipid Res., 1992a, 33:1765-76.
6. NJ Todd; JT Whicher; C Westacott; A Gilbert. Clin. Chim. Acta., 1990, 189:47-54.
7. TS Rao; JL Currie; AF Shaffer; PC Isakson. J. Pharmacol. Exp. Ther., 1994, 269:917-925.
8. BJ Van Lenten; SY Hama; FC de Beer; DM Stafforini; TM McIntyre; SM Prescott; BN La Du; AM Fogelman; M Navab. J. Clin. Invest., 1995, 96:2758-2767.
9. VG Cabana; JN Siegel; SM Sabesin. J. Lipid Res., 1989, 30:39-49.
10. JM McCord. Clin. Biochem., 1993, 26:351-7.
11. P Gregorevic; GS Lynch; D Williams. Eur. J. Appl. Physiol., 2001, 86:24-7.
12. CL Fattman; LM Schaefer; TD Oury. Free Radic. Biol. Med.,2003, 35:236-56.
13. M Kanter; O Coskun; F Armutcu; Y Uz Hulya; G Kizilay. Tohoku J. Exp. Med., 2005, 206. 155-162.
14. O Coskun; F Armutcu; M Kanter; GM Kuzey. J. Appl. Toxicol., 2005, 25: 8-12
15. V Vimal; T Devaki. Journal of Ethnopharmacology., 2004, 90: 151-154.
16. JA Berliner; JW Heinecke. Free Radic. Biol. Med., 1996. 20:707-727.
17. D Steinberg. J. Biol. Chem., 1997, 272: 20963-6.
18. B Frei. Crit. Rev. Food Sci. Nutr., 1995, 35: 83-98.
19. JT Willerson; PM Ridker. Inflammation as a cardiovascular risk factor. Circulation., 2004, 109:II2-II10.
20. MS Elkind. Inflammation, atherosclerosis, and stroke. Neurologist., 2006, 12:140-148.
21. H Wieland; D Seidel. J. Lipid Research., 1989, 24: 904-909.
22. W Patsch; SA Brown; JD Morrisett; AM Jr Gotto; JR Patsch. Clin. Chem., 1989, 35: 265-270.
23. IFF Benzie; JJ Strain. The FRAP assay. Analytical Biochem., 1996, 239: 70-76.
24. J Folch; N Lees; SG Stanley. J. Biol. Chem., 1957, 226: 497-509.
25. AK Sinha. Anal. Biochem., 1972, 47: 389-394.
26. P Kakkar; B Das; PN Viswanathan. Indian J. Biochem. Biophys., 1984, 21: 130-132.
27. DG Hafeman; RA Sunde; WG Hoekstra. J. Nutr., 1974, 104: 580-587.
28. I Carlberg; EB Mannervik. J. Biol. Chem., 1975. 250: 4475-4480.
29. CA Bennet; NL Franklin. Statistical Analysis in Chemistry and Chemical Industry. John-Wiley and Sons Inc., New York., 1967 p. 133.
30. W Khovidhunkit; RA Memon; KR Feingold; C Grunfeld. J. Infect. Dis., 2000, 181(Suppl3):S462-72.
31. W Khovidhunkit; MS Kim; RA Memon. J. Lipid Res., 2004, 45:1169-96.
32. MA Navarro; R Carpintero, S Aci{dotless}n. Immune-regulation of the apolipoprotein A-I/C-III/AIV gene cluster in experimental inflammation. Cytokine., 2005, 31: 52-63.
33. CD Gardner; SP Fortmann; RM Krauss. JAMA., 1996, 276:875-81.
34. BA Griffin; DJ Freeman; GW Tait; J Thomson; MJ Caslake; CJ Packard; J Shepherd. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis., 1994, 106:241-253.
35. B Lamarche; A Tchernof; S Moorjani. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation., 1997, 95: 69-75.
36. H Drexel; W Franz; RK Amann; C Neuenschwander; A Luethy; S Khan; F Follath. Am. J. Cardiol., 1992, 70: 436-440.
37. M Minhajuddin; J Iqbal; ZH Beg. Current Adv. Atheroscler. Res., 1999, 2: 120-128.
38. AA Qureshi; BA Bradlow; L Brace; J Manganello; DM Peterson; BC Pearce; JJK Wright; A Gapor; CE Elson. Response of hypercholesterolemia subjects to administration of tocotrienols. Lipids., 1995, 30: 1171-1177.
39. AA Qureshi; N Qureshi; JJK Wright. Am J Clin Nut., 1991, 53: 1021S-6S.
40. RA Parker; BC Pearce; RW Clark; DA Godan; JJK Wright. J. Biol. Che., 1993. 268: 11230-11238.
41. A Theriault; Q Wang; A Gapor; K Adeli. Arterioscler. Thromb. Vasc. Biol., 1999a, 19: 704-712.
42. C Gabay; I Kushner. N. Engl. J. Med., 1999, 340: 448-454.
43. JL Mehta; TGP Saldeen; K Rand. J. Am. Coll. Cardio., 1998, 31:1217-25.
44. F Nielsen; BB Mikkelsen; JB Nielsen; HR Andersen; P Grandjean. Clin. Chem., 1997, 43:1209-14.
45. HH Draper; M Hadley. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol., 1990, 186:421-31.
46. HR Andersen; JB Nielsen; F Nielsen; P Grandjean. J. Clin. Chem., 1997, 43: 562-8. S
47. M Inoue; IM Arias; JL Boyer; N Fausto; WB Jakoby; DA Schachter; DA Shafritz. The liver: biology and pathobiology. Raven Press: New York, USA., 1994, 443-59.
48. MB Yerer; S Aydoǧan; R Saraymen. Turk J. Biochem., 2006, 31: 124-128.